unknown
Stage
1
Investors
About
Cellaïon is a Walloon biotechnology company developing therapies for severe liver diseases; its lead product HepaStem® is in advanced clinical development for Acute-on-Chronic Liver Failure (ACLF). The company’s pipeline also includes indications such as acute toxic hepatitis, acute decompensation and non-alcoholic steatohepatitis (NASH).
Explore Cellaïon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.